MarketPeel
Insider Trading Intelligence
Pricing
…
ED

Eric M. Dube

TVTX
CHIEF EXECUTIVE OFFICER · TRAVERE THERAPEUTICS, INC. · CIK 0001763494
FILING MIX · LIFETIME38%/62%
BUYS
30
SELLS
49
TOTAL VALUE
$25.56M
COMPANIES
1
ACTIVE SINCE
Jan 2021
HOLDINGS NOW
432,886
AVG SELL PX
$28.62
TRADE KIND
SHOWING 79 / 79
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
41 backtested trades · 8 horizons · 47 pending
Forward-return performance of every backtestable P/S trade by Eric M. Dube, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d41+48.78%-0.02%+0.97%-0.99%-1.95%-0.95
14d41+51.22%+0.46%+0.88%-0.29%-2.52%-0.17
30d41+53.66%-0.14%+0.71%-0.85%-1.54%-0.36
60d41(1 pending)+60.00%+0.24%+0.71%-3.10%-2.88%-0.98
90d41(4 pending)+56.76%+5.06%+3.28%+0.73%-3.31%0.13
180d41(11 pending)+63.33%-5.49%+6.56%-12.05%-8.95%-1.47
1y41(13 pending)+53.57%+16.47%+11.88%+4.58%-12.32%—
2y41(18 pending)+73.91%+9.01%+20.41%-11.40%-39.30%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TVTX · 432,886 shares · as of May 6, 2026
0133,243266,487399,730532,97320222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 30 buys / 49 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
22,500$43.95$988.9K432,886May 6, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
22,500——455,386May 4, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,000——45,000May 4, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
22,500——22,500May 4, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,165$41.75$299.1K432,906Apr 15, 2026Apr 15, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
56,815$41.01$2.33M440,071Apr 15, 2026Apr 15, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20$42.66$853432,886Apr 15, 2026Apr 15, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
64,000——496,886Apr 13, 2026Apr 15, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
34,902$30.55$1.07M457,984Apr 1, 2026Apr 2, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
60,000——0Apr 1, 2026Apr 2, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
60,000$15.46$927.6K492,886Apr 1, 2026Apr 2, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
25,098$31.46$789.6K432,886Apr 1, 2026Apr 2, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
60,000$30.10$1.81M432,886Feb 20, 2026Feb 24, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
60,000$15.46$927.6K492,886Feb 20, 2026Feb 24, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
60,000——60,000Feb 20, 2026Feb 24, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
33,635$32.70$1.10M432,886Feb 3, 2026Feb 3, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
66,452$32.06$2.13M466,521Feb 3, 2026Feb 3, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
113,800——532,973Jan 31, 2026Feb 3, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
303,600——303,600Jan 31, 2026Feb 3, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
51,865$30.10$1.56M419,173Jan 27, 2026Jan 27, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
51,865——120,000Jan 27, 2026Jan 27, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
51,865$15.46$801.8K471,038Jan 27, 2026Jan 27, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
8,135——171,865Jan 23, 2026Jan 27, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,135$30.01$244.2K419,173Jan 23, 2026Jan 27, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
8,135$15.46$125.8K427,308Jan 23, 2026Jan 27, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
27,128$30.12$817.1K419,173Oct 29, 2025Oct 30, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
27,128$15.46$419.4K446,301Oct 29, 2025Oct 30, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
27,128——180,000Oct 29, 2025Oct 30, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
92,872$30.38$2.82M419,173Oct 28, 2025Oct 30, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
92,872——207,128Oct 28, 2025Oct 30, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
92,872$15.46$1.44M512,045Oct 28, 2025Oct 30, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
18,924$21.05$398.4K419,173May 5, 2025May 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
CHIEF EXECUTIVE OFFICER
18,924——438,097May 2, 2025May 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
18,924——18,924May 2, 2025May 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,375$24.04$273.5K419,173Feb 11, 2025Feb 12, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
50,691$20.21$1.02M430,548Feb 3, 2025Feb 4, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
260,000——260,000Jan 31, 2025Feb 4, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
130,000——481,239Jan 31, 2025Feb 4, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
10,736$19.46$208.9K351,239Jan 22, 2025Jan 23, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
21,125$11.52$243.4K361,975Sep 9, 2024Sep 9, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
32,500——383,100Sep 5, 2024Sep 9, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
9,106$8.53$77.7K360,616Feb 1, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
10,016$8.86$88.7K350,600Feb 1, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
360,000——360,000Jan 31, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
135,000——369,722Jan 31, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
CHIEF EXECUTIVE OFFICER
7,873$8.96$70.5K234,722Jan 23, 2024Jan 25, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
4,455$14.71$65.5K242,595Sep 5, 2023Sep 5, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,900——247,050Aug 31, 2023Sep 5, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
8,196$22.25$182.4K237,150Feb 1, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
32,500——32,500Jan 31, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
97,500——245,346Jan 31, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
260,000——260,000Jan 31, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
6,442$21.50$138.5K147,846Jan 24, 2023Jan 26, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
5,625$20.75$116.7K154,288Jan 5, 2023Jan 6, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
4,832$27.84$134.5K159,913Feb 10, 2022Feb 11, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,848——169,558Jan 31, 2022Feb 2, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
4,813$27.40$131.9K164,745Jan 31, 2022Feb 2, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
169,552——169,552Jan 31, 2022Feb 2, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,848——37,848Jan 31, 2022Feb 2, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
7,873$24.98$196.7K131,710Jan 24, 2022Jan 26, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
2,139$30.48$65.2K139,583Jan 5, 2022Jan 6, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
10,361$29.84$309.2K141,722Jan 5, 2022Jan 6, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
4,832$30.43$147.0K152,083Jan 4, 2022Jan 6, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
7,836$17.12$134.1K156,915Aug 17, 2021Aug 17, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,500——164,751Aug 13, 2021Aug 17, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
4,780$14.35$68.6K147,251Jun 2, 2021Jun 3, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
4,782$14.89$71.2K152,031Jun 1, 2021Jun 3, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
4,813$31.58$152.0K156,813Feb 8, 2021Feb 9, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
4,813$31.41$151.2K161,626Feb 5, 2021Feb 9, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
2,406$28.91$69.6K148,939Feb 3, 2021Feb 3, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,500——166,439Feb 3, 2021Feb 5, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
2,406$30.75$74.0K151,345Feb 2, 2021Feb 2, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
6,328$29.60$187.3K153,751Feb 2, 2021Feb 2, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——160,079Jan 31, 2021Feb 2, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
57,260——145,079Jan 21, 2021Jan 25, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
212,600——212,600Jan 21, 2021Jan 25, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
212,660——212,660Jan 21, 2021Jan 28, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
3,438$27.01$92.9K87,819Jan 6, 2021Jan 6, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Executive Officer
3,438$26.65$91.6K91,257Jan 5, 2021Jan 6, 2021 ↗View →
Other insiders · TVTX
Loading peer insiders…
About this filer
CIK 0001763494
ROLE
Chief Executive Officer
PRIMARY
TVTX
COMPANIES
1
ACTIVE SINCE
Jan 2021
MARKETPEEL · /INSIDER/0001763494DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback